Owen Smith
Director/Board Member at Locki Therapeutics Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stéphane Boissel | M | 56 |
SparingVision SAS
 SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | 4 years |
| Vasily Fedorin | M | - |
4BIO Ventures Management Ltd.
 4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | 9 years |
| Dmitry Kuzmin | M | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom.
University of Oxford
| 3 years |
| Andrey Kozlov | M | 48 |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | 10 years |
| Kieran Mudryy | M | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | 7 years |
| Laurent Arthaud | M | 61 |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | - |
| Edward McGill | M | - |
Locki Therapeutics Ltd.
 Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases.
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | 5 years |
| Joseph Papa | M | 68 |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | 1 years |
| Victoria Richon | M | 65 |
Entact Bio, Inc.
 Entact Bio, Inc. BiotechnologyHealth Technology Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions. | 2 years |
| Nathalie Trépo | F | - |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | 2 years |
| Owen Philip Smith | M | 38 |
Locki Therapeutics Ltd.
Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | - |
| Adrian Thrasher | M | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | - |
| Sabine Dandiguian | F | - |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | - |
| Johannes van der loo | M | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | - |
| Dimitri M Kullmann | M | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | - |
| Richard Gaster | M | 40 |
Locki Therapeutics Ltd.
Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | - |
| Paul Sieving | M | - |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | - |
| Sunyara Perez | F | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | 6 years |
| David Sheppard | M | 50 |
Locki Therapeutics Ltd.
Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | 5 years |
| Colin Walsh | M | 39 |
Locki Therapeutics Ltd.
Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | - |
| Natalie Johnston | F | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | 5 years |
| Benjamin Yerxa | M | 58 |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | - |
| Charlie Metcalfe | M | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | - |
| Brian McVeigh | M | 51 |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | 4 years |
| Leszek Lisowski | M | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | - |
| Alon Lazarus | M | 49 |
Locki Therapeutics Ltd.
Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | - |
| Kenya Honda | M | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | - |
| Karen Wagner | M | 54 |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | - |
| Philippe Fauchet | M | 65 |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | - |
| Mehdi Gasmi | M | 57 |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | 3 years |
| Andrew Sinclair | M | 52 |
Locki Therapeutics Ltd.
Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | - |
| Geoffroy de Ribains | M | - |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | - |
| Clive Stanway | M | 64 |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | - |
| Jeanne Cunicelli | F | 57 |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | - |
| Lorcan Murphy | M | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Benjamin Miles | M | - |
University of Bristol
| 8 years |
| Federico Ferrari | M | - |
University of Oxford
| 4 years |
| Adriana Vitagliano | F | - |
University of Oxford
| 2 years |
| Justin X. Wang | M | - |
University of Oxford
| 5 years |
| James Coates | M | - |
University of Oxford
| 6 years |
| Sandra Ainsua Martinez | F | - |
University of Oxford
| 5 years |
| Graeme Thompson | M | - |
University of Oxford
| 3 years |
| Ramasawmy Preetish | M | - |
University of Oxford
| 1 years |
| Rosalind Bazany | F | - |
University of Bristol
| 4 years |
| Marcel Maschmeyer | M | - |
University of Oxford
| 2 years |
| Max Lawson | M | - |
University of Bristol
| 3 years |
| Fabio Schneider | M | - |
University of Oxford
| 3 years |
| Tales Padilha | M | - |
University of Oxford
| 3 years |
| Archie Mason | M | - |
University of Bristol
| 4 years |
| Conor Sullivan | M | - |
University of Bristol
| 3 years |
| Antonia Whitecourt | F | - |
University of Bristol
| 4 years |
| Christopher Connolly | M | - |
University of Bristol
| 4 years |
| Luke Murphy | M | - |
University of Bristol
| 3 years |
| Robbie Gillespie | M | - |
University of Bristol
| 3 years |
| Timothy Stubbs | M | - |
University of Bristol
| 6 years |
| Jane Liew | F | - |
University of Oxford
| 4 years |
| James Greenwood | M | - |
University of Bristol
| 3 years |
| Yun Dan Xiao | F | 38 |
University of Bristol
| 3 years |
| Khalil Mair | M | - |
University of Oxford
| 3 years |
| Gina Shekerdemian | F | - |
University of Oxford
| 2 years |
| Nicola Metcalfe | F | - |
University of Bristol
| 3 years |
| Laura Gonzalez-Salmeron | M | - |
University of Oxford
| 3 years |
| Sophia Malashonok | F | - |
University of Oxford
| 1 years |
| Peder Beck-Friis | M | - |
University of Oxford
| 3 years |
| Mario Mazarese | M | - |
University of Bristol
| 3 years |
| Harry Gilfillan | M | - |
University of Oxford
| 3 years |
| Yi Du | M | - |
University of Oxford
| 1 years |
| Simon Costa | M | - |
University of Oxford
| - |
| Christian Huot | M | 40 |
University of Bristol
| 3 years |
| James Mallinson | M | 63 |
University of Oxford
| 10 years |
| Hao Wang | M | 41 |
University of Bristol
| 4 years |
| Hayden Ballard | M | - |
University of Bristol
| 4 years |
| Damien Hill | M | - |
University of Bristol
| 4 years |
| John Naylor-Leyland | M | 40 |
University of Bristol
| 3 years |
| Tom Elliott | M | - |
University of Bristol
| 3 years |
| Claes Styren | M | - |
University of Bristol
| 3 years |
| Samer Ibrahim Ahmed Al-Mofleh | M | - |
University of Bristol
| 3 years |
| Robyn Exton | M | - |
University of Bristol
| 3 years |
| Zi Feng Cui | M | 35 |
University of Bristol
| 4 years |
| Kathy Gromotka | F | - |
University of Oxford
| - |
| Sharad Raval | M | - |
University of Oxford
| 4 years |
| Kaj af Kleen | M | 42 |
University of Oxford
| 2 years |
| Sisa T Njongwe | M | - |
University of Oxford
| - |
| Mo Nin Ung | F | 55 |
University of Oxford
| 2 years |
| Freya Easton | F | - |
University of Oxford
| 4 years |
| Mauricio Awad | M | - |
University of Bristol
| 3 years |
| Zainab Usman | M | - |
University of Oxford
| 3 years |
| Dan Butman | M | - |
University of Oxford
| 4 years |
| Eliza Melkonyan | F | - |
University of Oxford
| 3 years |
| Lucas Wessling | M | - |
University of Oxford
| 3 years |
| Steven Futter | M | - |
University of Bristol
| 4 years |
| William An | M | - |
University of Oxford
| 4 years |
| Xiaohui Cao | M | - |
University of Bristol
| 3 years |
| Lachlan Ian Gowrie-Smith | M | 37 |
University of Bristol
| 3 years |
| Emma Moreby | F | - |
University of Oxford
| 4 years |
| Elena Kostova | F | - |
University of Oxford
| 3 years |
| James Scoon | M | - |
University of Oxford
| 4 years |
| Thomas Wernham | M | - |
University of Oxford
| 3 years |
| Fang Xin Li | M | 32 |
University of Oxford
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 87 | 87.88% |
| France | 11 | 11.11% |
| United States | 1 | 1.01% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Owen Smith
- Personal Network
